Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $32.2 million.

  • Xeris Biopharma Holdings' Net Cash Flow rose 2010.81% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year increase of 152.34%. This contributed to the annual value of $4.1 million for FY2024, which is 107.45% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Net Cash Flow stood at $32.2 million, which was up 3,711.95% from $845,000 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Net Cash Flow registered a high of $42.2 million during Q4 2022, and its lowest value of -$71.0 million during Q1 2023.
  • In the last 3 years, Xeris Biopharma Holdings' Net Cash Flow had a median value of -$27,000 in 2023 and averaged -$2.8 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Net Cash Flow tumbled by 294.47% in 2023 and then spiked by 5,751.85% in 2024.
  • Xeris Biopharma Holdings' Net Cash Flow (Quarterly) stood at $7.8 million in 2021, then skyrocketed by 442.41% to $42.2 million in 2022, then plummeted by 49.99% to $21.1 million in 2023, then crashed by 41.30% to $12.4 million in 2024, then skyrocketed by 2,010.81% to $32.2 million in 2025.
  • Its Net Cash Flow was $32.2 million in Q3 2025, compared to $845,000 in Q2 2025 and -$13.2 million in Q1 2025.